Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study [Usporedba dva selektivna antimuskarinska lijeka (solifenacin i darifenacin) u žena s prekomjerno aktivnim mokraćnim mjehurom]

But, Igor and Šprem Goldštajn, Marina and Orešković, Slavko (2012) Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study [Usporedba dva selektivna antimuskarinska lijeka (solifenacin i darifenacin) u žena s prekomjerno aktivnim mokraćnim mjehurom]. Collegium Antropologicum, 36 (4). pp. 1347-1353. ISSN 0350-6134

[img]
Preview
PDF - Published Version
Download (179kB) | Preview

Abstract

Overactive bladder (OAB) is a common, often debilitating, condition defined as urgency and urge incontinence, usually with frequency and nocturia. The use of muscarinic receptor antagonists are the mainstay of treatment, but their non-selectivity can result in unacceptable adverse effects that limit their usefulness. The purpose of this study was to evaluate 2 of the newer antimuscarinic agents, solifenacin and darifenacin, which demonstrate greater selectivity, in order to compare their tolerance and effectiveness. This was a multicentre, prospective, randomised, comparative (1:1) open-label study conducted in 4 centres comprising Slovenian gynaecologists and urologists. A total of 77 female patients with OAB were enrolled who received either solifenacin 5 mg or darifenacin 7.5 mg once daily. Study measurements consisted of changes in OAB symptoms and quality of life (QOL) evaluations after 1 and 3 months of treatment. Both treatment groups showing a reduction in all OAB symptoms but with no notable difference being seen between the 2 groups. Solifenacin though showed statistically greater improvements in QOL, better overall treatment satisfaction, and a decreased incidence of dry mouth after 3 months of treatment compared to the darifenacin group. This study demonstrates interesting initial results and indicates that these 2 drugs have a different profile that may confer an advantage to patients, but further methodologically rigorous studies comparing the use of solifenacin and darifenacin in OAB are required to establish the differences between these drugs over longer periods of treatment.

Abstract in Croatian

Prekomjerno aktivan mokraćni mjehur (OAB) je često stanje definirano urgencijom i urgentnom inkontinencijom, te učestalim dnevnim i noćnim mokrenjem. Terapija izbora danas je primjena antimuskarinskih lijekova. Medjutim, ograničavajući čimbenik primjene navedenih lijekova je njihova neselektivnost što može rezultirati neželjenim učincima i nuspojavama. Cilj ove studije je usporediti učinkovitost i podnošljivost solifenacina i darifenacina, dva novija visokoselektivna antimuskarinska lijeka. U multicentričnu, prospektivnu, randomiziranu »open-label« studiju uključeno je 77 pacijentica s OAB-om koje su uzimale 5 mg solifenacina ili 7.5 mg darifenacina u jednokratnoj dnevnoj dozi. Procjena učinkovitosti oba lijeka temeljila se na subjektivnoj i objektivnoj procjeni smanjenja OAB simptoma i kvalitete života nakon mjesec i tri mjeseca liječenja. U obje ispitivane skupine dokazana je podjednaka učinkovitost u smanjenju svih simptoma OAB-a. U skupini pacijentica koje su koristile solifenacin dokazano je statistički značajno poboljšanje kvalitete života, bolje ukupno zadovoljstvo i smanjena učestalost suhoće ustiju nakon tri mjeseca liječenja u usporedbi sa skupinom pacijentica koje su koristile darifenacin. Ova studija je dokazala da solifenacin i darifenacin predstavljaju učinkovite i dobro podnošljive lijekove u liječenju OAB-a. Rezultati ove studije da primjena oba lijeka s različitim profilom glede potencijalnih nuspojava može značajno poboljšati učinkovitost i sigurnost liječenja u pacijentica s OAB. Za nadati se da će buduće veće, prospektivne i randomizirane kliničke studije jasnije pozicionirati učinkovitost i podnošljivost solifenacina i darifenacina u žena s prekomjerno aktivnim mokraćnim mjehurom.

Item Type: Article
MeSH: Benzofurans / administration & dosage ; Benzofurans / adverse effects ; Female ; Humans ; Middle Aged ; Muscarinic Antagonists / administration & dosage ; Muscarinic Antagonists / adverse effects ; Prospective Studies ; Pyrrolidines / administration & dosage ; Pyrrolidines / adverse effects ; Quality of Life ; Quinuclidines / administration & dosage ; Quinuclidines / adverse effects ; Solifenacin Succinate ; Tetrahydroisoquinolines / administration & dosage ; Tetrahydroisoquinolines / adverse effects ; Treatment Outcome ; Urinary Bladder, Overactive / drug therapy
Departments: Katedra za ginekologiju i opstetriciju
Depositing User: Marijan Šember
Status: Published
Creators:
CreatorsEmail
But, IgorUNSPECIFIED
Šprem Goldštajn, MarinaUNSPECIFIED
Orešković, SlavkoUNSPECIFIED
Date: December 2012
Date Deposited: 26 Feb 2013 13:32
Last Modified: 08 Jul 2020 09:32
Subjects: /
Related URLs:
URI: http://medlib.mef.hr/id/eprint/1830

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year